Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Given Consensus Rating of “Moderate Buy” by Brokerages

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) has received a consensus recommendation of “Moderate Buy” from the five research firms that are currently covering the stock, Marketbeat.com reports. Two investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $12.40.

INO has been the subject of a number of analyst reports. Royal Bank of Canada cut their price target on Inovio Pharmaceuticals from $7.00 to $6.00 and set a “sector perform” rating for the company in a report on Friday, November 15th. Oppenheimer dropped their target price on Inovio Pharmaceuticals from $33.00 to $15.00 and set an “outperform” rating for the company in a research note on Monday, November 18th. JMP Securities reiterated a “market outperform” rating and issued a $18.00 target price on shares of Inovio Pharmaceuticals in a research note on Friday, January 10th. Finally, HC Wainwright dropped their target price on Inovio Pharmaceuticals from $5.00 to $3.00 and set a “neutral” rating for the company in a research note on Monday, January 13th.

Inovio Pharmaceuticals Stock Up 2.1 %

NASDAQ INO opened at $1.98 on Friday. Inovio Pharmaceuticals has a fifty-two week low of $1.74 and a fifty-two week high of $14.75. The stock has a market cap of $51.68 million, a price-to-earnings ratio of -0.94 and a beta of 0.89. The business has a fifty day moving average of $2.02 and a 200-day moving average of $4.33.

Institutional Investors Weigh In On Inovio Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in INO. FMR LLC increased its stake in Inovio Pharmaceuticals by 370.1% during the third quarter. FMR LLC now owns 27,261 shares of the biopharmaceutical company’s stock worth $158,000 after acquiring an additional 21,462 shares during the last quarter. BNP Paribas Financial Markets increased its stake in Inovio Pharmaceuticals by 177.0% during the third quarter. BNP Paribas Financial Markets now owns 5,681 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 3,630 shares during the last quarter. MetLife Investment Management LLC increased its stake in Inovio Pharmaceuticals by 129.1% during the third quarter. MetLife Investment Management LLC now owns 15,167 shares of the biopharmaceutical company’s stock worth $88,000 after acquiring an additional 8,546 shares during the last quarter. Atom Investors LP acquired a new stake in Inovio Pharmaceuticals during the third quarter worth about $103,000. Finally, State Street Corp increased its stake in Inovio Pharmaceuticals by 11.7% during the third quarter. State Street Corp now owns 490,662 shares of the biopharmaceutical company’s stock worth $2,836,000 after acquiring an additional 51,414 shares during the last quarter. 26.79% of the stock is currently owned by institutional investors and hedge funds.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.